NEXENTIS TECHNOLOGIES INC. Proceeds from Notes Payable
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Proceeds from Notes Payable of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-31
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for the quarter ending 2025-12-31 was $15.00K.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for the quarter ending 2025-03-31 was $1.10M.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for the quarter ending 2024-12-31 was $0.00.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for the quarter ending 2024-09-30 was $0.00.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for fiscal 2025 was $1.50M, a 3.09% increase from fiscal 2024.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for fiscal 2024 was $1.46M, a 107.86% increase from fiscal 2023.
- NEXENTIS TECHNOLOGIES INC. proceeds from notes payable for fiscal 2023 was $700.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.50M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $1.49M 10-Q · filed 2025-11-13 | |||
| 2025-03-31 | $1.10M 10-Q · filed 2025-05-15 | $1.10M derived: sum of 2 quarters · filed 2026-03-31 | $1.10M derived: sum of 3 quarters · filed 2026-03-31 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $1.46M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.46M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $1.46M 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $700.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |